期刊文献+

唑来膦酸联合放射性核素^(89)Sr静脉应用治疗前列腺癌转移性骨痛疗效观察 被引量:3

下载PDF
导出
摘要 目的观察唑来膦酸联合放射性核素89Sr治疗晚期前列腺癌骨转移性骨痛的疗效,评价其安全性。方法对16例未接受过放疗的晚期前列腺癌伴骨转移性疼痛患者采用唑来膦酸联合放射性核素89Sr治疗。结果治疗后3、6、9个月疼痛缓解率分别为81.3%、87.5%、100%,骨转移灶由治疗前的72个减少为治疗后的58个,出现轻度造血功能抑制5例。结论唑来膦酸联合放射性核素89Sr联治疗前列腺癌转移性骨痛安全、有效。
机构地区 淄博市中心医院
出处 《山东医药》 CAS 北大核心 2010年第46期50-51,共2页 Shandong Medical Journal
  • 相关文献

参考文献8

  • 1Pons F, Herrgnz R, Carcia A, et al. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast caner [J]. Eur J Nucl Med, 1997,24(10) :1210-1214.
  • 2中华人民共和国卫生部医政司.核医学诊断和治疗规范[M].北京:科学技术出版社.1997:292-295.
  • 3Serafini AN. Therapy of metastatic bone pain [ J ]. J Nucl Med, 2001,42 (6) : 895-906.
  • 4Hillegonds DJ, Franklin S, Shelton DK, et al. The management of painful bone metastases with an emphasis on radionuelide therapy [J]. J Natl Med Assoc, 2007,99(7) :785-794.
  • 5Kraeber-Bodere F, Campion L, Rousseau C, et al. Treatment of bone metastases of prostate cancer with strontium-89 chloride : Efficacy in relation to the degree of bone involvement [ J ]. Eur J Nuel Med ,2000,27 (10) : 1487-1493.
  • 6Zoner N, Keck AV, Pecherstoffer M. Comparative tolerability of drug therapies for hypercalcacmia of malignancy [ J ]. Drug Saf, 1999,21 (5) :389-406.
  • 7Lee CK, Aeppli DM, Unger J, et al. Strontium-89 chloride ( Metastron) for palliative treatment of bony metastases[J]. Am J Clin Oncol, 1996,19(2) :102-107.
  • 8Lam MG, Dahmane A, Stevens WH, et al. Combined use of zoledrenic acid and ^153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases[J]. Eur J Nucl Mol Imaging, 2008, 35(4) :756-765.

同被引文献20

  • 1孙达,褚玉,楼岑,王乾君,占宏伟,何刚强.^(89)SrCl_2治疗转移性骨肿瘤的临床应用[J].中华肿瘤杂志,2005,27(8):499-501. 被引量:14
  • 2徐健,程宇琪,吕昭萍,李喜枝,冯蕊,崔若梅.帕罗西汀和阿米替林治疗原发性纤维肌痛综合征的疗效和安全性对照研究[J].中国心理卫生杂志,2006,20(8):542-544. 被引量:9
  • 3张文乐 王秀问.唑来膦酸注射液治疗肿瘤溶骨性转移引起骨痛的二期临床研究.肿瘤防治杂志,2006,.
  • 4周际昌.实用肿瘤内科学[M].北京:北京科学技术出版社,2010:442-443.
  • 5Pons F, Herranz R, Garcia A, et al. Strontium 89 for palliation of pain from bone metastases in patients with prostate and breast cancer[J]. EurJ Nucl Med,1997,24(10):1210-1214.
  • 6Kushlinskii NE,Britvin TA,Abbagova SG,et al.Soluble Fag antigen in the serum of patients with colon cancer[J].Bull Exp Biol Med,2001,131 (4):361-363.
  • 7Jiang J,Ulbright TM,Zhang S,et al.Fag and Fag ligand exptession is elevated in prostatic in traepith-elial neoplagia and prostatic adenocarcinoma[J].Cancer,2002,95 (2),296-300.
  • 8Hefler L,Mayerhofer K,Nardi A,et al.Serum soluble Fas levels in ovarian cancer[J].Obstet Gynecol,2000,96(1):65-69.
  • 9Nomomura N,Nishimura K,Ono Y,et al.Soluble Fas in serum from patients with renal cell carcinoma[J].Urology,2000,55(2):151-155.
  • 10Sheen-Chen SM,Chen HS,Eng HL,et al.Circulating soluble fas in patients with breast cancer[J].World J Surg,2003,27(1):10-13.

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部